Glycyrrhetinic acid derivatives

A method of treating a condition or disease that benefits from an upregulation of PPARγ and/or a downregulation of the expression or activity of one or more specificity (Sp) proteins, comprising administering an effective amount of a compound of Formula (I):

• wherein
• R1 is selected from CN, halo, NO2, CO2R3, C1-6alkyl, fluoro-substituted C1-6alkyl, C2-6alkenyl, C2-6alkynyl, OR3, SR3, SOR3, SO2R3, NR3R4, C(O)NR3R4, C(O)R3, OC(O)R3, NHC(O)R3, P(O)R3R4, —C≡C—R3, —CR3═CR4R5, aryl and heteroaryl;
• R2 is selected from OC1-6alkyl, fluoro-substituted OC1-6alkyl, NH2, NHC1-6alkyl, N(C1-6alkyl)(C1-6alkyl), SH and SC1-6alkyl;
• R3, R4 and R5 are independently selected from H, C1-6alkyl, fluoro-substituted C1-6alkyl, aryl and heteroaryl;
• and
• one of X and Y is C═O while the other is CH2, and if X is C═O then adjacent to X represents a single bond and adjacent to Y represents a double bond and if Y is C═O then adjacent to Y represents a single bond and adjacent to X represents a double bond;
• and pharmaceutically acceptable salts, solvates and prodrugs thereof,
• to a subject in need thereof.